A surprising decision
According to the Straits Times, citing the New York Times, the FDA said the global clinical trial had not shown a statistically significant extension in patients’ survival. Summit Therapeutics disclosed the decision in a news release on Nov. 15, a day after the Nov. 14 review deadline the FDA had set earlier in the year.
Summit’s application sought approval for ivonescimab combined with chemotherapy for patients with EGFR-mutated non-small cell lung cancer previously treated with a third-generation tyrosine kinase inhibitor. The company estimated more than 14,000 patients in the United States could be eligible each year.
The HARMONi trial data
The application was based on the global phase 3 HARMONi trial, whose primary endpoints were progression-free survival and overall survival. The results painted a mixed picture:
- Ivonescimab clearly improved progression-free survival, cutting the risk of disease progression by about 48%.
- The overall survival endpoint did not reach statistical significance in the primary analysis, although it trended favourably.
- The drug’s safety profile was considered manageable, with VEGF-related side effects such as proteinuria, hypertension and bleeding.

















